An intrinsic mechanism of metabolic tuning promotes cardiac resilience to stress
-
Published:2024-09-13
Issue:
Volume:
Page:
-
ISSN:1757-4684
-
Container-title:EMBO Molecular Medicine
-
language:en
-
Short-container-title:EMBO Mol Med
Author:
Sorge MatteoORCID, Savoré GiuliaORCID, Gallo AndreaORCID, Acquarone DavideORCID, Sbroggiò Mauro, Velasco SilviaORCID, Zamporlini Federica, Femminò Saveria, Moiso Enrico, Morciano Giampaolo, Balmas Elisa, Raimondi Andrea, Nattenberg GabrielleORCID, Stefania Rachele, Tacchetti CarloORCID, Rizzo Angela MariaORCID, Corsetto Paola, Ghigo AlessandraORCID, Turco Emilia, Altruda Fiorella, Silengo Lorenzo, Pinton PaoloORCID, Raffaelli Nadia, Sniadecki Nathan J, Penna Claudia, Pagliaro Pasquale, Hirsch Emilio, Riganti Chiara, Tarone Guido, Bertero AlessandroORCID, Brancaccio MaraORCID
Abstract
AbstractDefining the molecular mechanisms underlying cardiac resilience is crucial to find effective approaches to protect the heart. A physiologic level of ROS is produced in the heart by fatty acid oxidation, but stressful events can boost ROS and cause mitochondrial dysfunction and cardiac functional impairment. Melusin is a muscle specific chaperone required for myocardial compensatory remodeling during stress. Here we report that Melusin localizes in mitochondria where it binds the mitochondrial trifunctional protein, a key enzyme in fatty acid oxidation, and decreases it activity. Studying both mice and human induced pluripotent stem cell-derived cardiomyocytes, we found that Melusin reduces lipid oxidation in the myocardium and limits ROS generation in steady state and during pressure overload and doxorubicin treatment, preventing mitochondrial dysfunction. Accordingly, the treatment with the lipid oxidation inhibitor Trimetazidine concomitantly with stressful stimuli limits ROS accumulation and prevents long-term heart dysfunction. These findings disclose a physiologic mechanism of metabolic regulation in the heart and demonstrate that a timely restriction of lipid metabolism represents a potential therapeutic strategy to improve cardiac resilience to stress.
Funder
Progetto di Ricerca di Interesse Nazionale 2015 Progetto di Ricerca Nazionale 2022 PNRR HHS | NIH | National Heart, Lung, and Blood Institute Associazione Italiana per la Ricerca sul Cancro Compagnia di San Paolo
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. Akki A, Smith K, Seymour AM (2008) Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem 311:215–224 2. Aon MA, Cortassa S, Marban E, O’Rourke B (2003) Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem 278:44735–44744 3. Arina P, Sorge M, Gallo A, Di Mauro V, Vitale N, Cappello P, Brazzi L, Barandalla-Sobrados M, Cimino J, Ranieri VM et al (2022) Modulation of LTCC pathways by a Melusin mimetic increases ventricular contractility during LPS-induced cardiomyopathy. Shock 57:318–325 4. Banke NH, Wende AR, Leone TC, O'Donnell JM, Abel ED, Kelly DP, Lewandowski ED (2010) Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res 107:233–241 5. Battault S, Renguet E, Van Steenbergen A, Horman S, Beauloye C, Bertrand L (2020) Myocardial glucotoxicity: mechanisms and potential therapeutic targets. Arch Cardiovasc Dis 113:736–748
|
|